Sanofi/Regeneron's Sarilumab Faces Stiff Competition Despite Humira Triumph
This article was originally published in Scrip
Executive Summary
Regeneron/Sanofi's IL-6 inhibitor sarilumab has beaten AbbVie's Humira (adalimumab) in a head to head trial. Top line Phase III results show sarilumab more significantly improved the signs and symptoms of rheumatoid arthritis after 24 weeks of treatment than blockbusting Humira did. The data will help differentiate the drug, but competition will remain fierce in the RA space, say analysts.